Vein thickness and inflammation in Behcet disease
Part of Eyes & vision, Genetic & congenital, Heart & circulation, Mouth & dental, Skin clinical trials.
This study looks at how the thickness of the femoral vein wall and certain markers of inflammation relate to Behcet disease. It may help doctors better understand and monitor the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with Behcet disease according to international criteria.
- You are able and willing to give your written consent to participate.
- You do not have other rheumatologic or vascular diseases.
- You do not have conditions like high blood pressure, diabetes, cancer, or active infections.
- You have not used aspirin or other anti-platelet medications in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a blood thinner (rivaroxaban) to standard immune therapy is better than immune therapy alone for treating blood clots in the legs caused by Behçet's disease. It may help prevent clots from getting worse or recurring.
This study looks at the health records and blood tests of children and young adults with Behçet disease to learn more about the condition. It also compares their results with healthy children to find clues that may help doctors better understand and treat Behçet disease.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
This study looks at levels of a protein called EBI-3 in the blood of people with Behçet's disease. It may help doctors better understand the disease and could lead to better diagnosis or treatment.
This trial tests whether adding a blood thinner (anticoagulant) to steroid therapy is more effective than steroids alone for treating deep vein thrombosis (a blood clot in a large vein) in people with Behçet's syndrome. It aims to find the best way to prevent future clots and reduce side effects.
This study looks at a protein called asprosin in people with Behçet's disease. It aims to see if asprosin levels are different in these patients, which could help understand the disease better.
Hear when a new Behçet trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.